Sagimet Biosciences, Inc. (SGMT)
9.43
+0.31
(+3.40%)
USD |
NASDAQ |
Nov 06, 10:39
Sagimet Biosciences Net Income (Quarterly) : -13.95M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -13.95M |
| March 31, 2026 | -10.65M |
| December 31, 2025 | -9.568M |
| September 30, 2025 | -12.91M |
| June 30, 2025 | -10.39M |
| March 31, 2025 | -18.18M |
| December 31, 2024 | -16.20M |
| September 30, 2024 | -14.62M |
| June 30, 2024 | -8.118M |
| Date | Value |
|---|---|
| March 31, 2024 | -6.629M |
| December 31, 2023 | -8.151M |
| September 30, 2023 | -6.353M |
| June 30, 2023 | -6.785M |
| March 31, 2023 | -6.587M |
| June 30, 2022 | -7.102M |
| March 31, 2022 | -8.735M |
| March 31, 2021 | -5.548M |
| March 31, 2020 | -3.983M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Vanda Pharmaceuticals, Inc. | -22.56M |
| IDEAYA Biosciences, Inc. | -125.75M |
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 13.95M |
| EPS Diluted (Quarterly) | -0.2627 |
| Enterprise Value | 325.27M |
| Earnings Yield | -13.59% |
| Normalized Earnings Yield | -13.59 |